Bone and matrix remodeling markers: A new tool for assessment of treatment efficacy in ankylosing spondylitis?

Journal of Rheumatology

Volumn 34, Issue 8, 2007, Pages 1647-1649

  Wendling, Daniel ^a   Toussirot, Eric ^a  

^a UNIVERSITY HOSPITAL OF BESANÇON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; COLONY STIMULATING FACTOR 1; ETANERCEPT; INFLIXIMAB; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOGENIC PROTEIN 1; OSTEOPROTEGERIN; STROMELYSIN; TRANSFORMING GROWTH FACTOR BETA;

ANKYLOSING SPONDYLITIS; BONE MASS; BONE MATRIX; BONE REMODELING; BONE TURNOVER; DISEASE ACTIVITY; DRUG EFFICACY; EDITORIAL; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

ANTIRHEUMATIC AGENTS; BIOLOGICAL MARKERS; BONE MATRIX; BONE MORPHOGENETIC PROTEINS; BONE REMODELING; HUMANS; IMMUNOGLOBULIN G; MACROPHAGE COLONY-STIMULATING FACTOR; MATRIX METALLOPROTEINASE 3; OSTEOPROTEGERIN; RECEPTORS, TUMOR NECROSIS FACTOR; SPONDYLITIS, ANKYLOSING; TRANSFORMING GROWTH FACTOR BETA; TREATMENT OUTCOME;

EID: 34547953963     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (16)

1. Wendling D. Bone loss in ankylosing spondylitis: can we put the puzzle together? J Rheumatol 2005;32:1184-5.
2. Woo JH, Lee HJ, Sung IH, Kim TH. Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept. J Rheumatol 2007;34:1753-9.
3. Spoorenberg A, van der Heijde D, de Klerk E, et al. Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease in ankylosing spondylitis. J Rheumatol 1999;26:980-4.
4. Anderson JJ, Baron G, van der Heijde D, et al. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001;44:1876-86.
5. Briot K, Garnero P, Le Henanff A, Dougados M, Roux C. Body weight, body composition and bone turnover changes in patients with spondyloarthropathy receiving anti-tumour necrosis factor alpha treatment. Ann Rheum Dis 2005;64:1137-40.
6. Franck H, Meurer T, Hofbauer LC. Evaluation of bone mineral density, hormones, biochemical markers of bone metabolism, and osteoprotegerin serum levels in patients with ankylosing spondylitis. J Rheumatol 2004;31:2236-41.
7. Kim HR, Kim HY, Lee SH. Elevated serum levels of soluble receptor activator of nuclear factor kappa B ligand (sRANKL) and reduced bone mineral density in patients with ankylosing spondylitis. Rheumatology Oxford 2006;45:1197-200.
8. Vis M, Havaardsholm EA, Haugeberg G. et al. Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NF-kappa-B ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 2006;65:1495-9.
9. Yang C, Gu J, Rihl M, et al. Serum levels of matrix metalloproteinase 3 and macrophage colony-stimulating factor 1 correlate with disease activity in ankylosing spondylitis. Arthritis Rheum 2004;51:691-9.
10. Chen CH, Lin KC, Yu DTY, et al. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity. Rheumatology Oxford 2006;45:414-20.
11. Maksymowych W, Poole R, Hiebert L, et al. Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis. J Rheumatol 2005;32:1911-7.
12. Maksymowych W, Landewe R, Conner-Spady B, et al. Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis [abstract]. Arthritis Rheum 2006;54 Suppl:S512.
13. Toussirot E, Racadot E, Nguyen NU, Dumoulin G, Wendling D. Absence of relation between TGFβ1 serum levels and bone mass in ankylosing spondylitis patients [letter]. Clin Exp Rheumatol 2000;18:111.
14. Wendling D, Racadot E, Cedoz JP, Dumoulin G. Serum IL-17, BMP 7, and bone turnover markers in patients with ankylosing spondylitis. Joint Bone Spine 2007;74:304-5.
15. You Z, DuRaine G, Tien JYL, et al. Expression of interleukin-17B in mouse embryonic limb buds and regulation by BMP-7 and bFGF. Biochemical Biophys Res Commun 2005;326:624-31.
16. Kim TH, Stone M, Payne U, et al. Cartilage biomarkers in ankylosing spondylitis. Relationship to clinical variables and treatment response. Arthritis Rheum 2005;52:885-91.